FlandersBio on Twitter

Follow us on Twitter

Archive for January 2014 - News

Archive for January 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

VIB and CD3 enter into a License and Collaboration Agreement with AstraZeneca for the development of MALT1 inhibitors

31.01.2014

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases. read more

Aratana Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering

30.01.2014

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the upsizing and pricing of its previously announced public offering. The size of the offering has been increased from 5,500,000 shares of common stock to 6,500,000 shares of common stock at a price to the public of $19.00 per share. A total of 5,000,000 shares are being offered by Aratana Therapeutics, and a total of 1,500,000 shares are being offered by certain selling stockholders. The Company has granted the underwriters a 30-day option to purchase up to 150,000 shares of common stock and a selling stockholder has also granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock. read more

First clinical centers opened for Phase 2 Crohn's study with GLPG0634

29.01.2014

Galapagos NV (Euronext: GLPG) announced today that the first clinical centers have been opened for enrolment in the Phase 2 clinical study in Crohn's disease with GLPG0634, a selective JAK1 inhibitor. The Phase 2 study will evaluate the efficacy and safety of GLPG0634 during 20 weeks of treatment in 180 patients with active Crohn's disease. read more

VIB scientists find new strategy to combat bacterial infections

29.01.2014

Increasing numbers of bacteria are developing antibiotic resistance. This forms a significant challenge in the battle against bacterial infections. Alvin Lo and Han Remaut (VIB/Vrije Universiteit Brussel) have identified a chemical substance with the potential of acting as a new drug to treat bacterial infections, particularly urinary tract infections. In contrast to the most popular antibiotics, this candidate drug does not destroy pathogenic bacteria, but rather disarms them. The benefit of this new strategy is that other (useful) bacteria are unharmed and there is a lower risk of the development and spread of resistance by bacteria. read more

MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014

29.01.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014). read more

PETX: Aratana Therapeutics Announces Conditional Approval of Second Canine-Specific Antibody Therapy

28.01.2014

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that the United States Department of Agriculture (USDA) has granted conditional approval for AT-005, Aratana’s canine-specific monoclonal antibody against CD52, which is intended as an aid in the treatment of T-cell lymphoma in dogs. AT-005 is Aratana’s second Canine Lymphoma Monoclonal Antibody to receive conditional approval and it represents Aratana’s first internal commercial opportunity. The company’s canine B-cell lymphoma therapy, AT-004, received conditional approval from the USDA in 2012 and was licensed to Novartis Animal Health Inc. for commercialization in United States and Canada. read more

Plant scientists unravel a molecular switch to stimulate leaf growth

24.01.2014

Mechanisms that determine the size of plants have fascinated plant scientists of all times, however they are far from understood. An international research team led by plant scientists from VIB and Ghent University report an important breakthrough in the scientific journal The Plant Cell. They identified a protein complex that controls the transition from cell division to cell specialization. By extending the activity of the complex during leaf growth, more cells divide, giving rise to larger leaves. These insights can now be used to guide plant breeding initiatives towards higher plant productivity. read more

TiGenix : to sell Dutch manufacturing facility to PharmaCell

24.01.2014

TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it has signed an agreement for the sale of its state-of-the-art Dutch production facility to PharmaCell B.V for a total consideration of EUR 5.75 million. PharmaCell, a leading European-based contract manufacturing organization active in the area of cell therapy and regenerative medicine, is to acquire the shares of TiGenix's wholly owned subsidiary TiGenix B.V., which holds the Dutch manufacturing facility. read more

MDxHealth Announces Agreement with Teva Pharmaceuticals for Commercialization of Two Cancer Tests in Israel

23.01.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an exclusive agreement with Teva Pharmaceuticals Ltd. for commercialization of ConfirmMDx® for Prostate Cancer and PredictMDx® for Glioblastoma tests in Israel. ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies. The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs. read more

New technology for the detection of genetic abnormalities which lead to serious epilepsy

22.01.2014

A European consortium of epilepsy researchers has reported the discovery of a new gene involved in severe childhood epilepsy. Using a novel combination of technologies, including trio exome sequencing of patient/parental DNA and genetic studies in the tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found that mutations in the gene CHD2 are responsible for a subset of epilepsy patients with symptoms similar to Dravet syndrome – a severe form of childhood epilepsy that is in many patients resistant to currently available anti-epileptic drugs. The discovery of CHD2’s role in epilepsy offers new diagnostic tools for families and clinicians of children with Dravet syndrome and related genetic epilepsies. In addition, the creation of a zebrafish model for CHD2 encephalopathy may facilitate the discovery of new drugs that can treat patients with this form of epilepsy. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print